What is the history of Medacta?
Medacta International was founded in 1999 by Alberto Siccardi in Castel San Pietro, Switzerland, starting as a specialized orthopaedic medical technology enterprise focused on designing, manufacturing, and distributing joint replacement systems, spine surgery instruments, and sports medicine products. The company gained global recognition through pioneering advancements in anterior approach hip replacement surgery, surgical education programs, and personalized knee replacement technology using 3D planning software. Through rigorous clinical research, physician training, and global expansion, Medacta evolved into a major publicly traded international medical device corporation listed on the SIX Swiss Exchange.
Related FAQs
Medacta Group SA is a publicly traded corporation listed on the SIX Swiss Exchange under the ticker symbol MOVE.
Medacta Group SA generates a strong annual net profit for the year scaling near 47.4 million euros, representing a stable net profit margin on overall business revenues.
Medacta Group SA officially completed its initial public offering and began trading its shares on the SIX Swiss Exchange on April 4, 2019, with an initial pricing of 96 Swiss francs per share.
Medacta International is a global medical technology enterprise that designs, manufactures, and distributes advanced orthopedic implants, surgical instruments, and specialized software solutions for joint replacement, spine surgery, and sports medici...
Interns participating in corporate, clinical research, and scientific internship programs at Medpace earn hourly wages and stipends structured around academic qualifications, functional departments, and geographic work locations.
Datamatics Global Services Limited officially completed its initial public offering and listed its equity shares on Indian stock exchanges, including the Bombay Stock Exchange and National Stock Exchange, in 2004.
Medacta is widely recognized by medical technology analysts and orthopedic surgeons as a high-quality, innovative global medical device company specializing in joint replacement, spine surgery, and sports medicine products.
Marqeta, Inc. officially completed its initial public offering, pricing its shares at twenty-seven dollars each on June 8, 2021, with trading on the Nasdaq Global Select Market commencing on June 9, 2021 under the ticker symbol MQ.
Francesco Siccardi, serving as the Chief Executive Officer of Medacta Group, receives a comprehensive annual remuneration package valued at approximately €2.00 million.
Medacta SA, a global medical technology enterprise specializing in the design, manufacture, and distribution of orthopedic implants, neurosurgical systems, and personalized mobile health solutions, is based in Castel San Pietro, Switzerland.